![Kanad D. Das](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanad D. Das
Directeur/Bestuurslid bij
Oncomyx Therapeutics, Inc.
Profiel
Kanad D.
Das has worked as an Investment Director at Boehringer Ingelheim (Venture Capital) since 2018.
He also currently holds Director positions at Actym Therapeutics, Inc. and Oncomyx Therapeutics, Inc.
Actieve functies van Kanad D. Das
| Bedrijven | Functie | Begin |
|---|---|---|
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Directeur/Bestuurslid | - |
Actym Therapeutics, Inc.
 Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Directeur/Bestuurslid | - |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01-05-2018 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
41
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Technology Services |
